Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 29, 2010

Premium

Title: TFIIS and GDOWN1 as Targets for Cancer Therapy

Patent Number: 7,704,967

Filed: March 7, 2007

Inventor: Averall Gnatt, University of Maryland

The invention "concerns cancer therapy related to the targeting of at least one core transcription factor," the patent's abstract states. "In particular, the compositions and methods of the invention concern targeting TFIIS, GDOWN1, or both for cancer therapy. In specific aspects, TFIIS and/or GDOWN1 inhibitors are employed for breast, prostate, pancreatic, and/or lung cancer."


Title: Methods and Materials for Treating Human Papillomavirus Infection

Patent Number: 7,704,965

Filed: June 26, 2003 PCT Filed: June 26, 2003

Lead Inventor: Gary Clawson, Pennsylvania State University

"The invention provides methods and materials related to treating HPV infections and HPV-associated conditions," the patent's abstract states.

The patent specifically claims the use of dsRNA to treat HPV infection.


Title: Methods of Detecting Mammalian Cells

Patent Number: 7,704,688

Filed: March 22, 2004

Lead Inventor: David Baulcombe, Plant Bioscience

The invention, the patent's abstract states, comprises methods "for screening of the occurrence of gene silencing in an organism. Also provided are methods for isolating silencing agents so identified."


Title: RIP140 Regulation of Diabetes

Application Number: 20100098638

Filed: Oct. 8, 2009

Lead Inventor: Michael Czech, University of Massachusetts (RXi Pharmaceuticals)

"Inhibition of RIP140 increases glucose transport," the patent application's abstract states. "Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport, treating obesity, increasing metabolism, and increasing brown fat."


Title: Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA

Application Number: 20100098663

Filed: Jan. 6, 2005 PCT Filed: Jan. 6, 2005

Lead Inventor: Robert Costa, University of Illinois

"The invention provides methods for inhibiting tumor cell proliferation by inhibiting FoxM1B, also called FoxM1, activity in a tumor cell," the patent application's abstract states. "The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules, wherein the siRNA molecules can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The invention further provides methods for preventing tumor growth, progression or both in an animal comprising inhibiting FoxM1B activity using siRNA molecules or pharmaceutical compositions comprising FoxM1B siRNA molecules."


Title: Lentiviral Vectors Allowing RNAi-Mediated Inhibition of GFAP and Vimentin Expression

Application Number: 20100098664

Filed: Nov. 28, 2007

Lead Inventor: Mathieu Jean-Francois Desclaux, Institut National de la Santé et de la Recherche Médicale

The invention, the patent application's abstract states, "relates to method for preventing, treating, or alleviating a central nervous system disorder using a non-replicative lentivirus comprising a lentiviral genome comprising a nucleic acid sequence producing at least one functional miRNA, at least one functional shRNA, and/or at least one functional siRNA … [capable of silencing] the expression of a gene that encodes a protein of the astrocyte cytoskeleton."

The invention further relates to "compositions and kits comprising such a lentivirus, as well as to uses thereof," the abstract adds.


Title: RNA Interference Tags

Application Number: 20100099191

Filed: April 10, 2007 PCT Filed: April 10, 2007

Lead Inventor: Wolfgang Biekle, Qiagen

"The invention relates to a composition for inhibiting the expression of a target gene in a eukaryotic cell by RNA interference," the patent application's abstract states. The composition of the invention comprises "a genetic construct and the target gene being introduced into the eukaryotic cell by means of said construct, and the construct having a first target gene and a first siRNA tag. The invention also relates to a composition for inhibiting the expression of one or more target genes in a eukaryotic cell by RNA interference.

"The composition comprises at least two genetic constructs, and the target genes are introduced into the eukaryotic cell by means of said constructs," it adds "The first construct [contains a] target gene and … [an] siRNA tag and the second construct containing [another] target gene and … siRNA tag. … [Both] the first and the second siRNA tag [have] different nucleic acid sequences."

According to the abstract the invention further "relates to a method for inhibiting the expression of a target gene in a eukaryotic cell … [that involves] providing at least one eukaryotic cell … capable of RNA interference; transfecting the cells with a composition according to the invention; and introducing at least one siRNA that is complementary to a siRNA tag of a transfected construct to inhibit the expression of the target gene that forms a transcription unit together with the siRNA tag."


Title: siRNA Targeting Fructose-1, 6-Bisphosphatase 1

Application Number: 20100099578

Filed: Dec. 3, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1."


Title: Methods and Compositions for RNAi-Mediated Inhibition of Gene Expression in Mammals

Application Number: 20100099740

Filed: Oct. 8, 2009

Lead Inventor: Mark Kay, Stanford University

"Methods and compositions are provided for modulating expression of a target sequence in mammals and mammalian cells in vivo," the patent application's abstract states. "In the subject methods, an effective amount of an RNAi agent … is introduced into a target cell. ... Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications."


Title: RNA Interference-Mediated Inhibition of Checkpoint Kinase-1 Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100099743

Filed: Dec. 17, 2009

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: RNA Interference-Mediated Inhibition of Matrix Metalloproteinase 13 Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100099744

Filed: Dec. 17, 2009

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MMP13 gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: Novel Nucleic Acid

Application Number: 20100099746

Filed: Dec. 18, 2007 PCT Filed: Dec. 18, 2007

Lead Inventor: Yoji Yamada, Kyowa Hakko Kirin

The invention, the patent application's abstract states, "provides a nucleic acid such as a microRNA or a microRNA precursor, having a novel sequence. The nucleic acid of the … invention is useful for detecting the expression or a mutation of a microRNA; separating cells; suppressing the expression of a gene having a target sequence; screening for a substance that promotes or suppresses a function of a microRNA; and diagnosing or treating a disease caused by a mast cell abnormality, a disease caused by an abnormality of mesenchymal stem cell proliferation or differentiation, cancers, and a disease caused by abnormal proliferation of cells, tissue hyperplasia, or the like."


Title: microRNA Molecules

Application Number: 20100099748

Filed: Aug. 31, 2009

Lead Inventor: Thomas Tuschl, Rockefeller University (Max Planck Institute)

"In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing," the patent application's abstract states. "Because the appearance of these short RNAs is regulated during development, they are also referred to as small temporal RNAs. We show that many more 21- and 22-[nucleotide long] expressed RNAs, termed microRNAs, exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated."


Title: RNA Interference-Mediated Inhibition of Muscarinic Cholinergic Receptor Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100099750

Filed: Dec. 10, 2009

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: RNAi-Mediated Expression Inhibition of a Cholinergic Protein

Application Number: 20100100978

Filed: June 9, 2009

Lead Inventor: Sylvie Berrard, Centre National de la Recherche Scientifique

The invention, the patent application's abstract states, "relates to nucleic acid sequences producing at least one functional miRNA, at least one functional shRNA, and/or at least one functional siRNA."

The miRNA, shRNA or siRNA of the invention is able to "silence the expression of a gene that encodes a cholinergic protein," it notes. The invention "further relates to compositions and kits comprising such nucleic acid sequences as well as to uses thereof."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.